Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Hualei Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Oncogene Proteins, Fusion, Repressor Proteins, Mutation. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Guangdong High-Level Hospital Construction Foundation, Shenzhen Fund for Guangdong Provincial High-Level Clinical Key Specialties, Shenzhen Key Medical Discipline Construction Fund.
Abstract (Originalsprache)
Background
ETV6::RUNX1 is the most common genetic abnormality in pediatric B‐cell acute lymphoblastic leukemia (ALL; ∼25%), yet the comprehensive genetic architecture and molecular predictors of intermediate‐risk (IR) stratification remain incompletely characterized.
Methods
We performed whole‐transcriptome sequencing (Illumina NovaSeq 6000, rRNA depletion, 41.70 Gb/sample) on bone marrow samples from 93 pediatric ETV6::RUNX1 ‐positive B‐ALL patients. Bioinformatics analysis included STAR alignment, MuTect2 variant calling, FusionCatcher fusion detection, and VEP annotation. The Jaccard index with permutation testing assessed mutation co‐occurrence; logistic regression identified independent predictors of IR classification.
Results
Beyond ETV6::RUNX1 , we identified 51 distinct fusion genes across the cohort, including the reciprocal RUNX1‐ETV6 (73.1%), chr8::KLF1210 (38.7%), and KLF12‐chr8 (34.4%). Somatic mutations in 249 genes were detected; the most frequent were KIAA1715 (17.2%), KRAS (11.8%), and NSD2 (10.8%). Network analysis revealed significant chromatin modifier co‐occurrence (KIAA1715‐KMT2C: J = 0.136, p = 0.015) and KRAS‐NRAS mutual exclusivity ( J = 0.000, p = 0.042). PTCH1 (OR = 3.50, 95% CI 0.21–58.49, p = 0.41) and GNB1 (OR = 6.5, 95% CI 1.2–34.8, p = 0.029) mutations independently predicted IR classification. chr8::KLF1210 fusion correlated with higher Day‐19 MRD levels ( p = 0.038).
Conclusions
GNB1 mutation represents a novel independent predictor of IR stratification in ETV6::RUNX1 ‐positive B‐ALL. The chromatin modifier co‐occurrence module and extensive fusion architecture reveal biological heterogeneity within this favorable‐risk subtype, with potential implications for risk‐adapted therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
- Department of Hematology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
ORCID-Profile: Hualei Luo, Guichi Zhou, Qiang Yao, Xue Tang, Huirong Mai, Xiaoying Fu
Förderung
- Guangdong High-Level Hospital Construction Foundation
- Shenzhen Fund for Guangdong Provincial High-Level Clinical Key Specialties
- Shenzhen Key Medical Discipline Construction Fund
- Shenzhen Clinical Research Center for Child Health and Disease
Zitieren
APA
Luo, H., Zhou, G., Li, Q., Yao, Q., Chen, Y., Tang, X., Liu, S., Ye, H., Mai, H., Fu, X., & Wang, Y. (2026). Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70636
Vancouver
Luo H, Zhou G, Li Q, Yao Q, Chen Y, Tang X, et al. Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70636
BibTeX
@article{Luo2026,
author = {Luo, Hualei and Zhou, Guichi and Li, Qian and Yao, Qiang and Chen, Yunsheng and Tang, Xue and Liu, Shilin and Ye, Huiying and Mai, Huirong and Fu, Xiaoying and Wang, Ying},
title = {Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70636}
}
EUVIMED